Why the study?
The incidence of pacing-induced cardiomyopathy in leadless pacemakers is less understood, particularly compared with transvenous pacemakers.
Does leadless pacemaker implantation reduce the incidence of pacing-induced cardiomyopathy compared to transvenous pacemakers in patients requiring ventricular pacing?
Does leadless pacemaker implantation reduce the incidence of pacing-induced cardiomyopathy compared to transvenous pacemakers in patients requiring ventricular pacing?
Leadless pacemakers and transvenous pacemakers have a similar incidence of pacing-induced cardiomyopathy, though patients with leadless pacemakers are less likely to undergo CRT upgrade.
Answers are grounded in this paper and cite their sources.
Does not support leadless preference to prevent cardiomyopathy; observational data leave open need for randomized confirmation.
BACKGROUND: Frequent nonphysiological ventricular pacing and resultant pacing-induced cardiomyopathy are well characterized in transvenous pacemakers (TVP). The incidence of pacing-induced cardiomyopathy in leadless pacemakers (LP) is less understood, particularly compared with TVP. METHODS: We utilized the TriNetX Analytics Network database to identify 2594 propensity score-matched patients who underwent implantation of LP and TVP between January 1, 2016, and January 1, 2023. The primary outcome was the incidence of pacing-induced cardiomyopathy, defined as a new diagnosis of systolic heart failure or a left ventricular ejection fraction <50%, occurring from the index hospitalization through December 2024, after excluding other etiologies of heart failure. RESULTS: The median age of the study population was 73.8 years (±15). Baseline left ventricular ejection fraction was similar between groups (LP: 63±7 versus TVP: 64±8). During a median follow-up period of 2.4 years, 422 incident cases of PCM occurred. Incidence rates of pacing-induced cardiomyopathy were comparable (LP: 7.6% versus TVP: 8.6%; P =0.187), including in patients with pacing indications of complete heart block or atrioventricular nodal ablation (LP: 10.3% versus TVP: 10.4%; P =0.948). The mean drop in left ventricular ejection fraction was comparable between both groups; however, patients with LP were less likely to undergo cardiac resynchronization therapy upgrade compared with those with TVP (LP: 9.7% versus TVP: 17.5%; P =0.014). CONCLUSIONS: The incidence and characteristics of pacing-induced cardiomyopathy are similar between LP and TVP. However, patients with LP are less likely to undergo cardiac resynchronization therapy upgrade.
No takes yet. Share an insight, caveat, or question.
Markson et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: